ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
125.034,63
1,36%
S&P 500
5.770,20
0,55%
US Dollar vs BRL
5,793
0,09%
Bitcoin
81.537,25
1,18%
Brent Oil
69,865
0,20%
As Melhores Corretoras Online
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. NeuroSense Therapeutics Ltd (NRSN)

  7. NeuroSense Therapeutics Ltd (NRSN) Notícias

NRSN

NeuroSense Therapeutics (NRSN)

NeuroSense Therapeutics Ltd
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:NRSN
DataHoraFonteTítuloCódigoCompanhia
06/01/202511:00PR Newswire (US)NeuroSense Regains Compliance with Nasdaq's Minimum Equity RequirementNASDAQ:NRSNNeuroSense Therapeutics Ltd
23/12/202411:00PR Newswire (US)NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALSNASDAQ:NRSNNeuroSense Therapeutics Ltd
18/12/202412:25PR Newswire (US)NeuroSense Provides Business Update and Third Quarter 2024 Financial ResultsNASDAQ:NRSNNeuroSense Therapeutics Ltd
11/12/202411:25PR Newswire (US)NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeCNASDAQ:NRSNNeuroSense Therapeutics Ltd
04/12/202410:30PR Newswire (US)NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALSNASDAQ:NRSNNeuroSense Therapeutics Ltd
02/12/202410:30PR Newswire (US)NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market PriceNASDAQ:NRSNNeuroSense Therapeutics Ltd
21/11/202411:20PR Newswire (US)NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MNDNASDAQ:NRSNNeuroSense Therapeutics Ltd
28/10/202409:30PR Newswire (US)NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA SubmissionNASDAQ:NRSNNeuroSense Therapeutics Ltd
24/10/202409:30PR Newswire (US)New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS PatientsNASDAQ:NRSNNeuroSense Therapeutics Ltd
15/10/202410:15PR Newswire (US)NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further UpdatesNASDAQ:NRSNNeuroSense Therapeutics Ltd
09/10/202410:00PR Newswire (US)NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in CanadaNASDAQ:NRSNNeuroSense Therapeutics Ltd
07/10/202410:00PR Newswire (US)NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual MeetingNASDAQ:NRSNNeuroSense Therapeutics Ltd
24/09/202410:05PR Newswire (US)NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer'sNASDAQ:NRSNNeuroSense Therapeutics Ltd
24/09/202410:00PR Newswire (US)NeuroSense Regains Compliance with NASDAQ Minimum Bid Price RuleNASDAQ:NRSNNeuroSense Therapeutics Ltd
30/08/202418:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
30/08/202417:30PR Newswire (US)NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price NotificationNASDAQ:NRSNNeuroSense Therapeutics Ltd
16/08/202417:05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:NRSNNeuroSense Therapeutics Ltd
07/08/202415:00PR Newswire (US)NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market PriceNASDAQ:NRSNNeuroSense Therapeutics Ltd
01/08/202410:15PR Newswire (US)NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical TrialNASDAQ:NRSNNeuroSense Therapeutics Ltd
09/07/202410:27PR Newswire (US)NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease ProgressionNASDAQ:NRSNNeuroSense Therapeutics Ltd
01/07/202409:00PR Newswire (US)NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying DrugNASDAQ:NRSNNeuroSense Therapeutics Ltd
24/06/202410:00PR Newswire (US)NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial ResultsNASDAQ:NRSNNeuroSense Therapeutics Ltd
21/06/202417:30PR Newswire (US)NeuroSense Receives Delisting Notice from Nasdaq and Intends to AppealNASDAQ:NRSNNeuroSense Therapeutics Ltd
20/05/202410:00PR Newswire (US)NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development SummitNASDAQ:NRSNNeuroSense Therapeutics Ltd
14/05/202410:05PR Newswire (US)NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine LearningNASDAQ:NRSNNeuroSense Therapeutics Ltd
07/05/202409:45PR Newswire (US)NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS PatientsNASDAQ:NRSNNeuroSense Therapeutics Ltd
02/05/202410:19PR Newswire (US)NeuroSense Announces First Quarter 2024 Business UpdateNASDAQ:NRSNNeuroSense Therapeutics Ltd
22/04/202409:30PR Newswire (US)NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's DiseaseNASDAQ:NRSNNeuroSense Therapeutics Ltd
18/04/202409:30PR Newswire (US)NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual MeetingNASDAQ:NRSNNeuroSense Therapeutics Ltd
12/04/202409:30PR Newswire (US)NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024NASDAQ:NRSNNeuroSense Therapeutics Ltd
 Apresentando as notícias mais relevantes sobre:NASDAQ:NRSN

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios